A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

As a lymphoma survivor, I struggle with the positivity trap — sometimes, I just want my fears validated instead of being ...

remains a useful treatment strategy, although the optimal timing of such approaches requires further clarification. Follicular lymphoma is a very diverse disease, and decisions to treat in the ...

And no one really thinks about the aftereffects of cancer treatment except those who have been through it and the medical personnel who provide ongoing care. I have follicular lymphoma, a form of ...

The FDA granted Crispr Therapeutics (CRSP) orphan status for its treatment of follicular lymphoma.Don't Miss Our End of Quarter Offers: ...

TAZVERIK ® is a registered trademark of Epizyme Inc., an Ipsen company.

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Roche has secured its first regulatory approval for mosunetuzumab, a first-in-class CD20xCD3 bispecific antibody, as a treatment for patients with follicular lymphoma (FL) in the EU.